cefotetan

{{Short description|Pharmaceutical drug}}

{{Drugbox

| Verifiedfields = changed

| verifiedrevid = 401948686

| IUPAC_name = (7S)-7-{[4-(1-amino-3-hydroxy-1,3-dioxopropan-2-ylidene)
1,3-dithietane-2-carbonyl]amino}-7-methoxy-
3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-
5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

| image = Cefotetan.svg

| width = 250

| tradename =

| Drugs.com = {{drugs.com|CDI|cefotetan}}

| pregnancy_AU =

| pregnancy_US = B

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US = Rx-only

| legal_status =

| routes_of_administration = Injection

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|correct|??}}

| CAS_number = 69712-56-7

| ATC_prefix = J01

| ATC_suffix = DC05

| PubChem = 53025

| DrugBank_Ref = {{drugbankcite|changed|drugbank}}

| DrugBank = DB01330

| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}

| ChemSpiderID = 47904

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 48SPP0PA9Q

| KEGG_Ref = {{keggcite|changed|kegg}}

| KEGG = D00260

| ChEBI_Ref = {{ebicite|changed|EBI}}

| ChEBI = 3499

| ChEMBL_Ref = {{ebicite|changed|EBI}}

| ChEMBL = 474579

| C=17 | H=17 | N=7 | O=8 | S=4

| smiles = O=C2N1/C(=C(\CS[C@@H]1[C@]2(OC)NC(=O)C3S/C(S3)=C(/C(=O)N)C(=O)O)CSc4nnnn4C)C(=O)O

| StdInChI_Ref = {{stdinchicite|correct|chemspider}}

| StdInChI = 1S/C17H17N7O8S4/c1-23-16(20-21-22-23)34-4-5-3-33-15-17(32-2,14(31)24(15)7(5)11(29)30)19-9(26)13-35-12(36-13)6(8(18)25)10(27)28/h13,15H,3-4H2,1-2H3,(H2,18,25)(H,19,26)(H,27,28)(H,29,30)/b12-6-/t13?,15-,17+/m1/s1

| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}

| StdInChIKey = SRZNHPXWXCNNDU-IXOPCIAXSA-N

}}

Cefotetan is an injectable antibiotic of the cephamycin type for prophylaxis and treatment of bacterial infections. It is often grouped together with second-generation cephalosporins and has a similar antibacterial spectrum, but with additional anti-anaerobe coverage.

Cefotetan was developed by Yamanouchi. It is marketed outside Japan by AstraZeneca with the brand names Apatef and Cefotan.